Medaxis, a leader in advanced wound care technologies, is pleased to announce the promotion of Blane Sanders to Chief Marketing and Product Officer. In this expanded executive role, Sanders will lead global marketing, product innovation, and portfolio strategy as Medaxis accelerates its growth and impact in the wound care market.

With more than 20 years of medical device leadership experience, Sanders has held key roles at KCI/3M and Medline, where he helped shape the commercialization of negative pressure wound therapy (NPWT) and other advanced wound healing technologies. Since joining Medaxis, Sanders has played a critical role in advancing product development and bringing new therapies to market.

“Blane’s deep understanding of the wound care landscape, combined with his strategic vision and relentless focus on execution, makes him the ideal leader to guide our marketing and product strategy,” said Jeffrey Castillo, Chief Executive Officer at Medaxis. “This promotion reflects both his contributions and our commitment to advancing innovation that truly matters to patients and clinicians alike.”

In his new capacity, Sanders will focus on accelerating the Medaxis product pipeline, deepening clinician partnerships, and expanding the company’s reach in key markets across the globe.

“It’s a privilege to step into this role during such a transformative period for Medaxis,” said Sanders. “We have a mission-driven team, an expanding portfolio, and a clear vision to redefine what’s possible in wound therapy. I’m excited to help lead the next chapter of growth.”